Investor Presentaiton

For personal use only Offer details Placement and Share Purchase Plan to raise $200M • Telix is conducting the Offer to raise $200 million, comprising: Offer Structure and Size Offer Price • an institutional placement to raise $175 million (Placement); and a Share Purchase Plan to raise up to $25 million (SPP). The Placement is being undertaken utilising the Company's existing Placement capacity under ASX Listing Rule 7.1. Approximately 22.727 million New Shares will be issued under the Placement and up to 3.248 million New Shares will be issued under the SPP. The Placement and the SPP will be conducted at the same Offer Price of $7.70 per New Share, which represents a: • 4.8% discount to the last closing price of $8.09 on Wednesday, 19 January 2022; and • 8.8% discount to the 5 day VWAP of $8.44 as at Wednesday, 19 January 2022. TELIX PHARMACEUTICALS Share Purchase Plan Co-Founder Sell-Down Ranking Joint Lead Managers Underwriting • SPP to existing eligible shareholders in Australia or New Zealand on the record date of 21 January 2022 (Eligible Shareholders), up to $30,000 per Eligible Shareholder. SPP Offer Booklet expected to be sent to Eligible Shareholders on Monday, 31 January 2022. Targeting a maximum of up to $25 million. SPP offer price of $7.70 per New Share, the same price as the Placement. Telix reserves the right (in its absolute discretion) to scale back applications under the SPP if demand exceeds $25 million. Concurrent with the Placement, the Company's Co-Founders (and Directors), Christian Behrenbruch and Andreas Kluge, have each agreed to sell 2 million shares at the Offer Price, representing 8.1% of each Co-Founder's shareholding. Each Co-Founder will hold 22.675 million Shares after the Sell-Down and each will hold approximately 7.3% of Telix's issued shares on completion of the Offer Christian Behrenbruch and Andreas Kluge have confirmed to Telix that they will not sell any further shares for at least 12 months from the date of settlement of the Sell-Down. New Shares issued under the Placement and SPP will rank equally with existing Telix ordinary shares from their respective issue dates. Jefferies (Australia) Pty Limited, Taylor Collison Limited and Wilsons Corporate Finance Limited are acting as Joint Lead Managers to the Placement. The Placement and SPP are not underwritten. Telix Pharmaceuticals Limited (ASX: TLX) 10

View entire presentation